Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling

IUBMB Life

Volumn 59, Issue 11, 2007, Pages 717-721

  Wang, Yu ^a   Zhao, Qiu ^a   Ma, Songlin ^a   Yang, Fang ^a   Gong, Yong ^a   Ke, Changshu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

HIF 1 ; mTOR; Pancreatic carcinoma; Sirolimus; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; VASCULOTROPIN;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VIVO STUDY; PANCREAS CARCINOMA; SIGNAL TRANSDUCTION;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PANCREATIC NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MAMMALIA;

EID: 35648987651     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1080/15216540701646484     Document Type: Article

References (25)

1. Sabers, C. J., Martin, M. M., Brunn, G. J., et al. (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270, 815-822.
2. Bjornsti, M. A., and Houghton, P. J. (2004) The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335-348.
3. Chan, S. (2004) Targeting the mammalian target of rapamycin(mTOR): a new approach to treating cancer. Br. J. Cancer 91, 1420-1424.
4. Huang, S., and Houghton, P. J. (2002) Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs 3, 295-304.
5. Abraham, R. T., and Wiederrecht, G. J. (1996) Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14, 483-510.
6. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732.
7. Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., and Abraham, R. T. (2002) Regulation of hypoxiainducible factor 1a expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22, 7004-7014.
8. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15, 551-578.
9. 2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514.
10. Wiederrecht, G. J., Sabers, C. J., Brunn, G. J., et al. (1995) Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog. Cell Cycle Res. 1, 53-71.
11. Hidalgo, M., and Rowinsky, E. K. (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686.
12. Mills, G. B., Lu, Y., and Kohn, E. C. (2001) Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR components of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 10031-10033.
13. Viqnot, S., Faivre, S., Aquirre, D., and Raymond, E. (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 16, 525-537.
14. Hay, N., and Sonenberq, N. (2004) Upstream and downstream of mTOR. Gene Dev. 18, 1926-1945.
15. Schmelzle, T., and Hall, M. N. (2000) TOR, a central controller of cell growth. Cell 103, 253-262.
16. Raught, B., Gingras, A. C., and Sonenberg, N. (2001) The target of rapamycin (TOR) proteins. Proc. Natl. Acad. Sci. USA 98, 7037-7044.
17. Semenza, G. L. (2000) HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88, 1474-1480.
18. Semenza, G. L. (2000) HIF-1 and human disease: one highly involved factor. Genes Dev. 14, 1983-1991.
19. Zhong, H., De Marzo, A. M., Laughner, E., et al. (1999) Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res. 59, 5830-5835.
20. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94, 8104-8109.
21. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18.
22. Kerbel, R. S. (2000) Tumor angiogenesis: past, present and near future. Carcinogenesis 21, 505-512.
23. Kerbel, R., and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727-739.
24. Cascinu, S., Staccioli, M. P., Gasparini, G., Giordani, P., et al. (2000) Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. 6, 2803-2807.
25. Niedergethmann, M., Hildenbrand, R., Wostbrock, B., et al. (2002) High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25, 122-129.